MedImmune Ventures, the corporate venturing unit of AstraZeneca, has helped Coferon, a US-based healthcare company, raise $12m.
The unit was joined in Coferon’s series B by venture firms Hatteras Venture Partners and Ascent Biomedical Ventures.
Dr. Colin Goddard, who had been acting as a part-time executive chairman for Coferon and was formerly chief executive of OSI Pharmaceuticals, before its $4 billion acquisition by Astellas Pharma in 2010, has becomeCoferon’s executive chairman.
Michael Gutch, managing director of MedImmune Ventures, said: “After extensive technical diligence we were all convinced of the enormous potential of this ground-breaking platform. Coferon’s highly experienced management team and strategy of a focused, capital-efficient development plan in the areas of epigenetic regulation and anti-infectives, combined with select collaborative partnerships, provides us with a compelling risk/reward proposition.”
The company is in the process of establishing its headquarters and laboratory at the Long Island High Tech Incubator on the campus…
